Breast cancer endocrine therapy has transformed from a relatively obscure treatment option to a cornerstone of breast cancer management over the past few decades (7–9), which has been fueled by the deepened understanding of the hormone receptor status in breast cancer cells (10, 11). This evidence concerns the gene NR4A1 and breast carcinoma.